Comparison of alternative models for linking drug exposure with adverse effects

Statistics in Medicine

Volumn 31, Issue 11-12, 2012, Pages 1014-1030

  Abrahamowicz, Michal ^a,b   Beauchamp, Marie Eve ^b   Sylvestre, Marie Pierre ^c,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cumulative effects; Goodness of fit; Model selection; Pharmacoepidemiology; Power; Time varying covariates

Indexed keywords

FLURAZEPAM;

ADVERSE DRUG REACTION; ARTICLE; BIOSTATISTICS; COMPARATIVE STUDY; CONTROLLED STUDY; COVARIANCE; DOSE RESPONSE; DRUG EXPOSURE; FALL RELATED INJURY; HUMAN; INJURY; MAJOR CLINICAL STUDY; PHARMACOEPIDEMIOLOGY; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; COMPUTER SIMULATION; DRUG TOXICITY; FLURAZEPAM; HUMANS; MODELS, STATISTICAL; PHARMACOEPIDEMIOLOGY;

EID: 84861201396     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.4343     Document Type: Article

References (46)

1. Skegg DCG. Evaluating the safety of medicines, with particular reference to contraception. Statistics in Medicine 2001;20:3557-3569.
2. Tamblyn R, Abrahamowicz M, du Berger R, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. Journal of the American Geriatrics Society 2005;53:233-241.
3. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?Annals of Internal Medicine 2004;141:102-112.
4. Bartlett G, Abrahamowicz M, Tamblyn R, Grad R, Capek R, du Berger R. Longitudinal patterns of new benzodiazepine use in the elderly. Pharmacoepidemiology and Drug Safety 2004;13:669-682.
5. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA. The risk of hospitalized infection in patients with rheumatoid arthritis. Journal of Rheumatology 2008;35:387-393.
6. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Annals of the Rheumatic Diseases 2007;66:308-312.
7. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis and Rheumatism 2006;54:628-634.
8. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology 2007;46:1157-1160.
9. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. Journal of Pharmacokinetics and Pharmacodynamics 2006;33:227-279.
10. Herings RMC, Stricker BH, de Beor A>, Bakker A>, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important that elimination half-life. Archives of Internal Medicine 1995;155:1801-1807.
11. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. American Journal of Medicine 1994;96:254-259.
12. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, Esdaile JM. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?Arthritis & Rheumatism-Arthritis Care & Research 2008;59:169-175.
13. Hauptmann M, Wellmann J, Lubin JH, Rosenberg PS, Kreienbrock L. Analysis of exposure-time-response relationships using a spline weight function. Biometrics 2000;56:1105-1108.
14. Vacek PA. Assessing the effect of intensity when exposure varies over time. Statistics in Medicine 1997;16:503-513.
15. Abrahamowicz M, Bartlett G, Tamblyn R, du Berger R. Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. J Clin Epidemiol 2006;59:393-403.
16. Sylvestre MP, Abrahamowicz M. Flexible modelling of the cumulative effects of time-dependent exposures on the hazard. Statistics in Medicine 2009;28:3437-3453.
17. Milliken C, Cooper SJ. Withdrawal symptoms from paroxetine. Human Psychopharmacology-Clinical and Experimental 1998;13:217-219.
18. Bespalov A>, Jongen-Relo AL, Van Gaalen M, Harich S, Schoemaker H, Gross G. Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics 2007;320:944-950.
19. MacKenzie T, Abrahamowicz M. Marginal and hazard ratio specific random data generation: applications to semi-parametric bootstrapping. Statistics and Computing 2002;12:245-252.
20. Abrahamowicz M, MacKenzie T, Esdaile JM. Time-dependent hazard ratio: modeling and hypothesis testing with application in lupus nephritis. Journal of the American Statistical Association 1996;91:1432-1439.
21. Sylvestre MP, Abrahamowicz M. Comparison of algorithms to generate event times conditional on time-dependent covariates. Statistics in Medicine 2008;27:2618-2634.
22. PermAlgo: Permutational algorith to generate event times conditional on a covariate matrix including time-dependent covariates. R package. Version 1.0; 2010.
23. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control 1974;AC-19:716-723.
24. Volinsky CT, Raftery AE. Bayesian information criterion for censored survival models. Biometrics 2000;56:256-262.
25. Quantin C, Abrahamowicz M, Moreau T, Bartlett-Esquilant G, MacKenzie T, Tazi MA, Lalonde L, Faivre J. Variation over time of the effects of prognostic factors in a population based study of colon cancer: comparison of statistical models. American Journal of Epidemiology 1999;150:1188-1200.
26. Benedetti A>, Abrahamowicz M, Goldberg MS. Accounting for data-dependent degrees of freedom selection when testing the effect of a continuous covariate in generalized additive models. Communications in Statistics-Simulation and Computation 2009;38:1115-1135.
27. R Development Core Team. R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing:Vienna, Austria, 2010.
28. Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox Regression Model. Statistics in Medicine 1989;8:771-783.
29. Hastie TJ, Tibshirani RJ. Generalized Additive Models, Chapman & Hall/CRC:New York, 1990.
30. Neutel CI, Hirdes JP, Maxwell CJ, Patten SB. New evidence on benzodiazepine use and falls: the time factor. Age & Ageing 1996;25:273-278.
31. Canadian Pharmacists Association. Benzodiazepines. Compendium of Pharmaceuticals and Specialties. Ottawa, ON; 2005.
32. Yang YH. Can the strengths of AIC and BIC be shared? A conflict between model indentification and regression estimation. Biometrika 2005;92:937-950.
33. Ramsay JO. Monotone regression splines in action (with discussion). Statistics in Science 1988;3:425-461.
34. Abrahamowicz M, MacKenzie T. Joint estimation of time-dependent and non-linear effects of continuous covariates on survival. Statistics in Medicine 2007;26:392-408.
35. Hastie T, Tibshirani R. Exploring the nature of covariate effects in the proportional hazards model. Biometrics 1990;46:1005-1016.
36. Kooperberg C, Stone CJ, Truong YK. Hazard regression. Journal of the American Statistical Association 1995;90:78-94.
37. Automated data systems available for pharmacoepidemiology studies, In Pharmacoepidemiology, Strom BL (ed), John Wiley & Sons Ltd, Chichester, 2010;217-346.
38. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006;17:268-275.
39. Abraham NS, Castillo DL, Hartman C. National mortality following upper gastrointestinal or cardiovascular events in older veterans with recent nonsteroidal anti-inflammatory drug use. Alimentary Pharmacology & Therapeutics 2008;28:97-106.
40. Walker AM. Confounding by indication. Epidemiology 1996;7:335-336.
41. McMahon AD. Approaches to combat with confounding by indication in observational studies of intended drug effects. Pharmacoepidemiology and Drug Safety 2003;12:551-558.
42. Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiology and Drug Safety 2010;19:537-554.
43. Abrahamowicz M, Tamblyn R. Drug utilization patterns, In Encyclopedia of Biostatistics, Armitage P, Colton T (eds), 2nd ed., John Wiley & Sons, Ltd, Chichester, 2005;1533-1553.
44. Sun LQ, Zhou X. Inference in the additive risk model with time-varying covariates subject to measurement errors. Statistics & Probability Letters 2008;78:2559-2566.
45. Berhane K, Hauptmann M, Langholz B. Using tensor product splines in modeling exposure-time-response relationships: application to the Colorado Plateau Uranium Miners cohort. Statistics in Medicine 2008;27:5484-5496.
46. Richardson DB. Latency models for analyses of protracted exposures. Epidemiology 2009;20:395-399.